NYSE - Delayed Quote • USD
West Pharmaceutical Services, Inc. (WST)
At close: April 26 at 4:00 PM EDT
After hours: April 26 at 4:58 PM EDT
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 8 | 8 | 9 | 9 |
| Avg. Estimate | 1.9 | 2.12 | 7.67 | 9.04 |
| Low Estimate | 1.54 | 2.06 | 7.59 | 8.54 |
| High Estimate | 2.1 | 2.21 | 7.89 | 9.5 |
| Year Ago EPS | 2.11 | 2.16 | 8.08 | 7.67 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 8 | 8 | 9 | 9 |
| Avg. Estimate | 749.25M | 785.74M | 3.01B | 3.28B |
| Low Estimate | 714.21M | 775M | 3B | 3.24B |
| High Estimate | 768.1M | 792.8M | 3.02B | 3.35B |
| Year Ago Sales | 755.71M | 747.4M | 2.95B | 3.01B |
| Sales Growth (year/est) | -0.90% | 5.10% | 2.10% | 9.10% |
Earnings History
| CURRENCY IN USD | 6/30/2023 | 9/30/2023 | 12/31/2023 | 3/31/2024 |
|---|---|---|---|---|
| EPS Est. | 1.93 | 1.86 | 1.78 | 1.26 |
| EPS Actual | 2.11 | 2.16 | 1.83 | 1.56 |
| Difference | 0.18 | 0.3 | 0.05 | 0.3 |
| Surprise % | 9.30% | 16.10% | 2.80% | 23.80% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | 1.9 | 2.12 | 7.67 | 9.04 |
| 7 Days Ago | 1.99 | 2.11 | 7.62 | 9.05 |
| 30 Days Ago | 1.99 | 2.11 | 7.62 | 9.05 |
| 60 Days Ago | 1.98 | 2.1 | 7.61 | 9.05 |
| 90 Days Ago | 2.28 | 2.19 | 8.8 | 9.92 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | 1 | 2 | 4 | 1 |
| Up Last 30 Days | 1 | 2 | 4 | 1 |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | 3 | 2 | -- | 2 |
Growth Estimates
| CURRENCY IN USD | WST | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | -10.00% | -- | -- | 6.50% |
| Next Qtr. | -1.90% | -- | -- | 12.00% |
| Current Year | -5.10% | -- | -- | 5.30% |
| Next Year | 17.90% | -- | -- | 13.10% |
| Next 5 Years (per annum) | 6.87% | -- | -- | 11.09% |
| Past 5 Years (per annum) | 27.05% | -- | -- | -- |
Research Analysis
Upgrades & Downgrades
| Maintains | UBS: Neutral to Neutral | 2/16/2024 |
| Maintains | Keybanc: Overweight to Overweight | 2/13/2024 |
| Upgrade | Jefferies: Hold to Buy | 2/7/2024 |
| Maintains | Stephens & Co.: Overweight to Overweight | 10/27/2023 |
| Maintains | Keybanc: Overweight to Overweight | 8/30/2023 |
| Maintains | Keybanc: Overweight to Overweight | 8/21/2023 |
Related Tickers
RMD ResMed Inc.
218.06
+18.89%
RGEN Repligen Corporation
166.58
+0.56%
TFX Teleflex Incorporated
206.71
0.00%
COO The Cooper Companies, Inc.
88.84
-1.21%
BDX Becton, Dickinson and Company
231.55
+0.46%
ATR AptarGroup, Inc.
143.33
+2.25%
BAX Baxter International Inc.
40.13
-0.25%
HOLX Hologic, Inc.
75.98
+0.36%
DIM.PA Sartorius Stedim Biotech S.A.
208.30
+2.41%
STVN Stevanato Group S.p.A.
27.54
+0.07%